Struggling With Adoption, Sickle Cell Gene Therapy Manufacturers Embrace CMS Model

 
• By Tim Casey
  
Analysts think the model could allow more Medicaid coverage of cell and gene therapies for sickle cell disease. (Shutterstock)

More from Cell & Gene Therapies

More from Medicaid